GRAIL, Inc. (GRAL) Stock Price & How to Invest

GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement.

The investment picture is a classic high-growth, high-burn diagnostics profile. Revenue is real and growing quickly (Galleri volumes rose about 50% year over year in Q1 2026), but the company runs large losses as it funds commercial scale-up, clinical trials, and manufacturing. GRAIL submitted a premarket approval (PMA) application to the FDA in January 2026 and has a large cash cushion, so the story hinges on whether Galleri wins regulatory approval, gets added to screening guidelines, and secures Medicare and commercial reimbursement that would move it from a cash-pay niche to a mass-market screening tool.

GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.

8 analysts publish price targets on GRAL, averaging $70.12 against a $68.56 price as of August 2026, or +2.3%. The published targets run from $56.00 to $88.00, a moderate spread, and the ratings split 4 buy, 5 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GRAL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on GRAIL, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Galleri volume and revenue growth. Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. The most optimistic published target, $88.00, assumes this works close to its best case.

The case against. GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The most pessimistic target, $56.00, is roughly what GRAL is worth if this bites instead.

Read the full bull and bear case on GRAL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see GRAIL, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$156M
• Q1 2026 revenue (YoY): ~$40.8M (+28%)
• Net loss (TTM): ~-$395M
• Cash & short-term investments: ~$823M
• Market cap: ~$3.0B
• Price / sales (TTM): ~17x

GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.

Other names that sit close to GRAL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GRAL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GRAL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GRAL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

GRAL is a pre-profit, single-product diagnostics bet where Galleri's growth, its pending FDA approval, and eventual insurance coverage matter far more than any current earnings multiple.

Whether GRAL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GRAL a buy or a sell?, and where the stock could go from here in the GRAL stock forecast.

For income investors, whether GRAL pays a dividend and how the payout looks is covered in does GRAL pay a dividend? And to weigh GRAL against a peer, read the full side-by-side comparisons: GRAL vs GH and GRAL vs ILMN.